CAS 98319-24-5
:3-oxo-4-aza-5A-androstane-17B-(N-tert-butylcarboxamide)
- 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androstan-3-one
- 3-Oxo-4-Aza-5A-Androstane-17B-(N-T-Butyl)Carboxamide
- (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
- Androstane-N-terbutyl-3-oxo-4-aza-5 alfa-17 beta-carboxamide
- 17-Beta-(N-Butylcarbamoyl)-4-Aza-5-Alpha-Androstan-3-One
- 17β-(t-Butylcarbamoyl)-4-aza-5a-androstan-3-one
- Dihydroproscar
- N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide
- Dihydro Finasteride
(4AR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
CAS :Formule :C23H38N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.56003-Oxo-4-aza-5A-androstane-17-β-(N-tert-butylcarboxamide); 98%
CAS :Formule :C23H38N2O2Degré de pureté :(HPLC) ≥ 98.0%Couleur et forme :White to off-white powderMasse moléculaire :374.56Dihydroproscar
CAS :Formule :C23H38N2O2Degré de pureté :≥ 95.0% (anhydrous basis)Couleur et forme :White to off-white powderMasse moléculaire :374.56Finasteride EP Impurity A
CAS :Formule :C23H38N2O2Couleur et forme :White To Off-White SolidMasse moléculaire :374.57N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androstane-17β-carboxamide (Dihydrofinasteride)
CAS :Produit contrôléFormule :C23H38N2O2Couleur et forme :NeatMasse moléculaire :374.56Dihydro Finasteride
CAS :Impurity Finasteride EP Impurity A
Applications Dihydro Finasteride (Finasteride EP Impurity A) is the reduced product of Finasteride (F342000): a mechanism-based inhibitor of human prostate and skin steroid 5α-reductase. It forms an enzyme-bound NADP-dihydrofinasteride adduct during this inhibitory process.
References Bull, H.G. et al.: Am. J. Chem. Soc., 118, 2359 (1996); Liang, T. et al.: Endocrinol., 117, 571 (1985); Ellsworth, K.P. et al.: J. Steroid Bioche. Mol. Biol., 66, 271 (1998);Formule :C23H38N2O2Couleur et forme :Off-WhiteMasse moléculaire :374.56Dihydroproscar
CAS :Dihydroproscar is a synthetic retinoid that is clinically used to treat benign prostatic hyperplasia (BPH). It has been shown to inhibit the synthesis of 3β-hydroxysteroid, which is necessary for the conversion of testosterone to dihydrotestosterone. Dihydroproscar also has a denaturing effect on proteins and inhibits the in vitro synthesis of DNA and RNA. The second-order rate constant for the reaction of dihydroproscar with ribonucleotides is about 1.4 times faster than that for other retinoids. Dihydroproscar has pharmacokinetic properties that are similar to those of other retinoids, including fatty acids and hydrogen chloride.
Formule :C23H38N2O2Degré de pureté :Min. 97 Area-%Couleur et forme :PowderMasse moléculaire :374.56 g/mol3-Oxo-4-aza-5-α-androstane-17-β-N-t-butylcarboxamide
CAS :Formule :C23H38N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.569









